EPIDIOLEX® (cannabidiol) oral solution: Now FDA Approved, Pending Rescheduling
Click here to see Press Release.

Sign up here to receive EPIDIOLEX information and availability updates.

News

Greenwich Biosciences Inc., is the US subsidiary of GW Pharmaceuticals plc. For general corporate information, please click here.

Investor Inquiries

Stephen Schultz
Vice President, Investor Relations
Tel: +1 917.280.2424 Direct
Email
Fax: 760.795.2219

Media Inquiries

Stephen Schultz
Vice President, Investor Relations
Tel: +1 917.280.2424 Direct
Email
Fax: 760.795.2219

No recent news to display.

Dec 21, 2017
At the AES Annual Meeting 2017 in Washington, DC, Greenwich Biosciences will continue its commitment to advance cannabinoid science by sponsoring several events and posters, including:
Jun 22, 2017
On June 23rd, we will join individuals and advocacy organizations across the globe as they participate in events to increase awareness about Dravet syndrome, a rare, severe form of childhood-onset epilepsy.
group of professional people
Mar 22, 2017
GREENWICH Biosciences is growing. We are excited to announce that GREENWICH Biosciences, the U.S. subsidiary of GW Pharmaceuticals, has moved in order to accommodate our growing U.S. team.

Pages